SK Capital Completes Strategic Investment in Ecopol
14.9.2023 07:30:00 EEST | Business Wire | Press release
Ecopol S.p.A. (“Ecopol” or the “Company”), a leading developer and producer of innovative biodegradable films and delivery systems, announced today the completion of a strategic investment from affiliates of SK Capital Partners, LP (“SK Capital”), a leading private investment firm focused on the specialty materials, ingredients, and life sciences sectors. SK Capital has acquired a majority interest in the Company with Mauro Carbone, Ecopol’s CEO and controlling shareholder, retaining a significant stake and remaining as both the CEO and largest individual shareholder. It is also announced the formation of a new Board of Directors, which includes industry leaders with extensive experience across sustainable materials and consumer packaged goods (“CPG”) markets in Ecopol’s value chains, including Jan-Dirk Auris, E. Craig Mitchell, Daniele Ferrari and Dave Mezzanotte.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230913054522/en/
“Ecopol is pleased to begin our partnership with SK Capital and to be working with a diverse team of high-impact industry executives who have joined our Board of Directors,” said Mauro Carbone, Ecopol CEO. “I am excited for the next chapter of our journey as we work together to accelerate Ecopol’s rapid growth and continue to make strategic investments to provide even greater value for our global customer base and bring more sustainable solutions to both existing and new markets. We are grateful to Roberto Quagliuolo, Luca Bucelli and Laurent Labatut for their contributions as former Board Directors and look forward to Tikehau Capital’s continued support as an ongoing minority shareholder.”
“In partnership with Mauro, we have assembled a world-class Board of Directors who will be highly impactful in helping Ecopol execute its strategic priorities and achieve its vision to become the global leader in highly innovative and sustainable delivery systems,” added Stephen D’Incelli, Managing Director at SK Capital. “We look forward as a Board to supporting Mauro and his leadership team in driving Ecopol’s next phase of transformational growth.”
In connection with the closing, SK Capital and Mauro have appointed the following Board Directors:
Jan-Dirk Auris spent over 35 years at Henkel AG & Co. KGaA (“Henkel”), where he served in a variety of senior executive roles and as a member of the Henkel Management Board. He most recently led Henkel’s Adhesives Technologies business unit, where he had extensive experience serving leading global CPG companies. Mr. Auris played a leading role in implementing a new performance management playbook across Henkel and driving innovation and sustainability initiatives.
E. Craig Mitchell has over 35 years of experience in the specialty materials industry and currently serves as President, Flavors and Extracts Group at Sensient Technologies Corporation. He previously served in critical roles at global leaders in Ecopol’s supply chain, including President and COO of Sekisui Specialty Chemicals America, LLC, a manufacturer of polyvinyl alcohol, as well as VP of Sales, Americas of Celanese Corporation, a producer of vinyl acetate monomer.
Daniele Ferrari will serve as Board Chairman. Mr. Ferrari, who is based full-time in Italy, has over 35 years of experience in the specialty materials industry, most recently as the CEO of Versalis S.p.A., the largest chemical company in Italy, and as Chairman of Matrìca S.p.A., a joint-venture with Novamont, a leader in the bio-plastics industry at the forefront of renewable chemistry. Mr. Ferrari has served as a Senior Director at SK Capital and brings significant sustainability leadership in prior roles as President of the European Chemical Industry Council (“CEFIC”), President of Plastics Europe, and as a board member of the Alliance to End Plastics Waste.
Dave Mezzanotte has over 40 years of experience in the specialty materials and packaging industries and has served as a Senior Director at SK Capital since 2018. He previously was Chairman and CEO of Coveris, a global manufacturer of flexible consumer packaging, and CEO of CHEP, a global logistics services provider for CPGs.
The Board of Directors also includes Mauro Carbone, Ecopol CEO and significant minority investor; Stephen d’Incelli, Deal Lead and Managing Director at SK Capital; and Josh Lieberman, Principal at SK Capital.
Latham & Watkins LLP served as legal counsel to SK Capital. Lead arrangers and bookrunners Crédit Agricole Italia S.p.A. and Intesa Sanpaolo S.p.A provided committed financing in support of the transaction. Legance and Alpeggiani Studio Legale Associato served as legal counsel and STS Deloitte served as tax advisor to Ecopol. UBS served as financial advisor.
About Ecopol
Ecopol is a leading global producer of water-soluble and biodegradable films. The Company’s innovative delivery systems for unit-dose applications allow the world’s leading brands to significantly reduce CO2 emissions and the usage of water and virgin plastic throughout their supply chains. Headquartered in Chiesina Uzzanese, Tuscany, Ecopol operates production campuses in Italy and the United States, providing the highest levels of service, technical support and innovation partnership to its worldwide customer base. For more information, please visit www.ecopol.com.
About SK Capital
SK Capital is a private investment firm with a disciplined focus on the specialty materials, ingredients and life sciences sectors. The firm seeks to build resilient, sustainable and growing businesses that create substantial long-term economic value. SK Capital aims to utilize its industry, operating and investment experience to identify opportunities to transform businesses into higher performing organizations with improved strategic positioning, growth and profitability, as well as lower operating risk. SK Capital’s portfolio of businesses generates revenues of approximately $17 billion annually, employs more than 25,000 people globally, and operates more than 200 plants in over 30 countries. The firm currently has approximately $7.8 billion in assets under management. For more information, please visit www.skcapitalpartners.com.
About Tikehau Capital
Tikehau Capital is a global alternative asset management group with €41.1 billion of assets under management (as of 30 June 2023). Tikehau Capital has developed a wide range of expertise across four asset classes (private debt, real assets, private equity and capital markets strategies) as well as multi-asset and special opportunities strategies. Leveraging its strong equity base (€3.1 billion of shareholders’ equity as of 30 June 2023), the firm invests its own capital alongside its investor-clients within each of its strategies. Controlled by its managers alongside leading institutional partners, Tikehau Capital is guided by a strong entrepreneurial spirit and DNA, shared by its 742 employees (as of 30 June 2023) across its 15 offices in Europe, the Middle East, Asia and North America. Tikehau Capital is listed in compartment A of the regulated Euronext Paris market (ISIN code: FR0013230612; Ticker: TKO.FP). For more information, please visit www.tikehaucapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230913054522/en/
Contact information
Jeremy Milner
BackBay Communications
jeremy.milner@backbaycommunications.com
(401) 862-9422
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
